GlassScriptPhysician profile
George A Nikias
NPI 1679585236
$6,005.02
in general payments reported to CMS, 2019-2025
30 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $224 · 2021: $794 · 2022: $1,183 · 2023: $1,032 · 2024: $1,112 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,808.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,063.61 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $740.00 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $614.79 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $607.42 | 2021-2024 | Zeposia |
| Pfizer INC. | $584.93 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $438.48 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $269.33 | 2021-2025 | |
| Ardelyx, INC. | $201.97 | 2022-2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $196.23 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $164.55 | 2019-2024 | Dificid, Zinplava |
| Genzyme Corporation | $157.38 | 2023-2024 | |
| Medical Device Business Services, INC. | $146.58 | 2024 | Linx Reflux Management System |
| Madrigal Pharmaceuticals | $130.98 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $123.56 | 2019-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $98.14 | 2024-2025 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $81.72 | 2021-2024 | Suflave, Sutab |
| Ucb, INC. | $56.97 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $56.42 | 2023-2025 | Dupixent |
| Capsovision, INC. | $37.72 | 2023 | Capsocam Plus |
| Lilly USA, LLC | $36.19 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $34.56 | 2021-2022 | |
| Medtronic, INC. | $28.04 | 2022 | |
| Boston Scientific Corporation | $26.59 | 2022-2023 | Spyglass |
| Ipsen Biopharmaceuticals, INC | $18.37 | 2025 | Iqirvo |
| Novo Nordisk INC | $16.67 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $16.00 | 2023 | Linzess |
| W. L. Gore & Associates, INC. | $15.85 | 2023 | Gore Cardioform Septal Occluder |
| Aimmune Therapeutics, INC. | $14.59 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.85 | 2023 | Cyltezo |
| Vivus LLC | $13.53 | 2025 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Nikias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.